JPI InvestFrançais
JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool's data · not financial advice · full analysis (free)
All stocksHealth CareRMD › Financials

ResMed (RMD): financial analysis & fundamentals

Health Care · price $236 · market cap $34.0 B
In short — ResMed trades at 22.6× earnings (P/E), 17.8× expected earnings, for a PEG of 9.41 and a net margin of 27%. Revenue growth 9%. Quick verdict: expensive (the market prices high growth).

📈 See the interactive version (live chart) →

🔗 Related pages on ResMed — Are analysts right?  ·  If I had invested  ·  Dividend

Valuation & profitability

MetricValueWhat it means
P/E (price / earnings)22.6The higher, the more growth the market expects.
Forward P/E17.8On next year's expected earnings. Lower than current P/E = rising earnings.
PEG (P/E ÷ growth)9.41Below 1 = cheap given growth; above 2 = expensive.
Net margin27%Share of revenue that ends up as profit.
Revenue growth9%Pace of revenue growth.
Price-to-book5.2Price relative to book value.
Market cap$34.0 BTotal market value of the company.
Dividend yield1.19%Annual dividend ~$2.40/share relative to price.

Income statement (by year)

YearRevenueNet incomeNet margin
2023$4.2 B$898 M21%
2024$4.7 B$1.0 B22%
2025$5.1 B$1.4 B27%
2026$5.7 B$1.5 B27%

📊 Open the interactive ResMed page (charts, live news) →

Frequently asked questions

Is ResMed stock expensive?

ResMed has a P/E of 22.6 (forward P/E 17.8) and a PEG of 9.41. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: expensive (the market prices high growth).

What is ResMed's net margin?

ResMed's net margin is about 27% — the share of revenue that ends up as net profit.

What is ResMed's revenue?

Latest known revenue: $5.7 B for net income of $1.5 B. The year-by-year breakdown is in the income statement above.

What is ResMed's market cap?

ResMed (RMD) has a market cap of about $34.0 B.

Does ResMed pay a dividend?

Yes: ResMed pays about $2.40/share per year, i.e. roughly a 1.19% yield at the current price.

What is JPI Invest?

JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.

Explore JPI Invest for free → How it works: the method →

⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.